Adagene to Participate in Two Upcoming Investor Conferences May 12, 2026 08:30AM
Adagene presents trial data showing muzastotug combination benefits Apr 17, 2026 04:01PM
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types Apr 17, 2026 04:01PM
Adagene adds Peter Lebowitz to scientific advisory board Apr 14, 2026 07:01AM
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board Apr 14, 2026 07:00AM
View Older Stories

Apr 2, 2026 07:10AM Adagene prices $70 million public offering at $3.75 per ADS
Apr 2, 2026 07:10AM Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
Apr 2, 2026 07:01AM Adagene partners with Incyte for cancer drug combination study
Apr 2, 2026 07:01AM Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable
Apr 2, 2026 07:00AM Adagene reports higher response rates with increased muzastotug dosing
Apr 2, 2026 07:00AM Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Re
Apr 1, 2026 05:00PM Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
Mar 17, 2026 04:35PM Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA
Feb 17, 2026 09:27AM Adagene to Participate in Two Upcoming Investor Conferences
Jan 23, 2026 08:00AM Adagene Provides Business Update and 2026 Objectives
Dec 16, 2025 07:00AM Adagene receives FDA fast track status for cancer drug muzastotug
Dec 16, 2025 07:00AM Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
Nov 13, 2025 07:03AM Adagene licenses SAFEbody technology to Third Arc Bio for $5M upfront
Nov 13, 2025 07:00AM Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
Oct 31, 2025 07:00AM Adagene doses first patient in phase 2 colorectal cancer study
Oct 31, 2025 07:00AM Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorec
Sep 16, 2025 08:00AM Adagene expands Exelixis partnership for third masked ADC development
Sep 16, 2025 08:00AM Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
Sep 5, 2025 09:55AM Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China
Sep 3, 2025 09:05AM Adagene names Axel Hoos as executive advisor
Sep 3, 2025 09:05AM Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor
Aug 26, 2025 08:05AM Adagene to Participate in Two Investor Conferences in September
Aug 12, 2025 04:05PM Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates
Jul 15, 2025 07:01AM Adagene receives FDA guidance for phase 2 colorectal cancer trial
Jul 15, 2025 07:00AM Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA
Jul 8, 2025 07:01AM Adagene (ADAG) partners with ConjugateBio for antibody drug conjugate development
Jul 8, 2025 07:00AM Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate
Jul 1, 2025 07:02AM Adagene (ADAG) announces up to $25 million strategic investment from Sanofi (SNY)
Jul 1, 2025 07:00AM Adagene announces up to $25 million strategic investment from Sanofi
May 27, 2025 07:30AM Adagene to Present at Jefferies Global Healthcare Conference 2025
May 22, 2025 05:08PM Adagene Inc. (ADAG) updates data from Phase 1b/2 study of Muzastotug
May 22, 2025 05:05PM Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annu
Apr 28, 2025 08:00AM Adagene Appoints John Maraganore, Ph.D. as Executive Advisor
Apr 23, 2025 10:05AM Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 7, 2025 08:00AM Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum
Mar 24, 2025 08:00AM Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update
Mar 13, 2025 08:00AM Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit
Mar 6, 2025 08:00AM Adagene to Present at Leerink’s Global Healthcare Conference 2025
Feb 27, 2025 08:00AM Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer
Jan 27, 2025 07:01AM Adagene Inc. (ADAG) Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA
Jan 27, 2025 07:00AM Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
Jan 27, 2025 07:00AM Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
Jan 21, 2025 05:00PM Adagene Inc. (ADAG) to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA
Jan 21, 2025 05:00PM Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
Jan 14, 2025 08:00AM Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025
Nov 7, 2024 10:01AM Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Mono
Oct 9, 2024 06:00AM Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Sep 16, 2024 03:01AM Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metas
Aug 29, 2024 07:00AM Adagene to Participate in Investor Conferences in September
Jul 25, 2024 04:05PM Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update
View Older Stories